Приказ основних података о документу

Dostupnost lekova za retke bolesti - komparativna analiza legislativnih zahteva između Srbije, Hrvatske i Makedonije

dc.creatorKrajnović, Dušanka
dc.creatorArsić, Jasmina
dc.creatorTasić, Ljiljana
dc.creatorPetrova, Guenka
dc.creatorMilijić, Svetlana
dc.date.accessioned2019-09-02T12:05:09Z
dc.date.available2019-09-02T12:05:09Z
dc.date.issued2018
dc.identifier.issn0365-4478
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/3115
dc.description.abstractAccess to orphan drugs (In EU regulation Orphan Drugs are referred as Orphan Medicinal Products (OMP)) is a key role in determining whether patients with rare diseases (RDs) will receive adequate and efficient treatment. The objective of this article is to identify differences in patient access to orphan drugs in 3 pharmaceutical markets: Serbia, Croatia and Macedonia. Patient access was defined: as the market access (availability) and affordability (financial accessibility). We analysed the legislative requirements for the authorisation process and made a cross country comparison. Retrospective cross-sectional analysis was done on drug lists in selected countries and a cross-comparison between the List of Orphan Drugs in Europe (LODE) for a six-month period (May 2014-October 2014). We included all 179 OMPs marketed in EU in our analysis, which had received market authorization in Croatia upon its membership in the EU. Total number of marketed drugs in Serbia was 59 (32.96%) drugs and in Macedonia 52 (29.05%) drugs. However, market authorization does not guarantee patient access to any given drug, so only 39.11% of OMPs could be accessed by Croatian patients (70 drugs).The number of refunded drugs in Serbia and Macedonia was smaller (32 and 20, respectively) which makes respectively, 17.88% and 11.17% of drugs on the LODE. The present study showed some variations between countries in selected indicators of availability and access to orphan drugs. Patients in Croatia had greater number of registered and refunded drugs, but in Serbia more than a half of registered OMPs could be refunded from National Health Insurance Fund. Macedonia had smaller number of inhabitants and also had the smaller number of patients from certain RDs which results in lower total number of OMPs.en
dc.description.abstractDostupnost lekova za retke bolesti (orfan lekovi, u EU regulativi koristi se izraz na engleskom Orphan medicinal products, OMP) igra važnu ulogu u tome da li će bolesnici sa retkim bolestima imati pristup efikasnoj i adekvatnoj terapiji. Ciljevi ovog rada su da se identifikuju razlike u pristupu bolesnika orfan lekovima u tri odabrane zemlje: Srbiji, Hrvatskoj i Makedoniji. Pristup orfan lekovima definisana je kao: tržišna pristupačnost (dostupnost) i priuštivost (finansijska pristupačnost). Analizirali smo legislativne zahteve u procesu stavljanja leka u promet i uradili komparaciju među posmatranim zemljama. Retrospektivnom studijom preseka poredili smo nacionalne liste lekova posmatranih zemalja i Listu orfan lekova u EU, za period od šest meseci (maj-oktobar 2014.). Od ukupno 179 OMP, koliko ih je u tom periodu bilo sa dozvolom za stavljanje u promet u EU, u Srbiji je bilo registrovano 59 (32,96%), u Makedoniji 52 (29,05%), dok su u Hrvatskoj učlanjenjem u EU svi registrovani lekovi postali tržišno dostupni. Međutim, dozvola za stavljanje u promet nije i garancija da bolesnik ima pristup datom leku, pa je samo 39,11% lekova sa dozvolom za stavljanje u promet bilo na listi lekova koje se refundiraju u Hrvatskoj (70 OMP). Broj lekova kojima bolesnici imaju pristup preko nacionalnih fondova zdravstvenog osiguranja u Srbiji i Makedoniji su manji (32 OMP i 20OMP, respektivno), što čini da je priuštivost lekova u Srbiji tek 17,88% , a u Makedoniji 11,17% od liste orfan lekova u EU. Broj lekova, fizička i finansijska pristupačnost u analiziranim zemljama nije ista, dok je u Hrvatskoj bolesnicima dostupan najveći broj registrovanih lekova, u Srbiji se više od polovine registrovanih OMP može refundirati o trošku RFZO. Makedonija zbog manjeg broja stanovnika ima manji broj obolelih od RB, što rezultira manjim brojem OMP.sr
dc.publisherUniverzitet u Nišu - Medicinski fakultet, Niš
dc.relationinfo:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41004/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175036/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceActa medica Medianae
dc.subjectorphan medicinal product (OMP)en
dc.subjectaffordabilityen
dc.subjectavailabilityen
dc.subjectrare diseasesen
dc.subjectlegislative requirementsen
dc.subjectorfan lekovi (OMP)sr
dc.subjectpriuštivostsr
dc.subjectdostupnostsr
dc.subjectretke bolestisr
dc.subjectlegislativni zahtevisr
dc.titleAccess to orphan drugs: A cross country comparison of legislative approach among Serbia, Croatia and Macedoniaen
dc.titleDostupnost lekova za retke bolesti - komparativna analiza legislativnih zahteva između Srbije, Hrvatske i Makedonijesr
dc.typearticle
dc.rights.licenseBY
dcterms.abstractТасић, Љиљана; Крајновић, Душанка; Петрова, Гуенка; Милијић, Светлана; Aрсић, Јасмина; Доступност лекова за ретке болести - компаративна анализа легислативних захтева између Србије, Хрватске и Македоније; Доступност лекова за ретке болести - компаративна анализа легислативних захтева између Србије, Хрватске и Македоније;
dc.citation.volume57
dc.citation.issue4
dc.citation.spage43
dc.citation.epage51
dc.citation.other57(4): 43-51
dc.citation.rankM51
dc.identifier.doi10.5633/amm.2018.0406
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/1709/3113.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу